Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

The Motley Fool. DATE Thursday, Apr 24, 2025 Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. CALL PARTICIPANTS Daniel O'Day: Chairman and Chief ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) ...

Truist Financial analyst Asthika Goonewardene maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of ...

Winners of the ADGHW Innovation Awards 2025 addressed prenatal gene editing, robotic organ transplantation, precision drug delivery, and novel pain ...

Gilead Sciences Inc. closed 13.61% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences Inc. closed 15.47% short of its 52-week high of $119.96, which the company reached on March 10th.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24 ...